The estimated Net Worth of Anik Shabbir is at least $217 Mille dollars as of 3 March 2023. Shabbir Shabbir owns over 16,625 units of Sutro Biopharma Inc stock worth over $216,896 and over the last 6 years he sold STRO stock worth over $0. In addition, he makes $0 as Chief Technical Operations Officer at Sutro Biopharma Inc.
Shabbir has made over 8 trades of the Sutro Biopharma Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 16,625 units of STRO stock worth $76,641 on 3 March 2023.
The largest trade he's ever made was exercising 16,625 units of Sutro Biopharma Inc stock on 3 March 2023 worth over $76,641. On average, Shabbir trades about 5,392 units every 105 days since 2018. As of 3 March 2023 he still owns at least 47,049 units of Sutro Biopharma Inc stock.
You can see the complete history of Shabbir Shabbir stock trades at the bottom of the page.
Dr. Shabbir T. Anik, Ph.D. is Chief Technical Operations Officer of the Company. From August 2011 to December 2015, Dr. Anik served as Senior Vice President of Technical Operations at Onyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing medicines for the treatment of cancer. Previously, Dr. Anik served as President and Chief Executive Officer of Althea Technologies Inc., President of Global Pharmaceutical Development Services and Chief Scientific Officer for Patheon Inc. and in various leadership positions at Neurex Corporation and Syntex Inc. Dr. Anik received a B.S. in Pharmacy from the University of Bombay, a Ph.D. in Pharmaceutical Sciences from the University of Wisconsin, Madison and an M.B.A. from Santa Clara University.
Shabbir Anik is 67, he's been the Chief Technical Operations Officer of Sutro Biopharma Inc since 2016. There are 1 older and 19 younger executives at Sutro Biopharma Inc. The oldest executive at Sutro Biopharma Inc is Dr. Shabbir T. Anik, 68, who is the Chief Technical Operations Officer.
Anik's mailing address filed with the SEC is C/O SUTRO BIOPHARMA, INC, 111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080.
Over the last 6 years, insiders at Sutro Biopharma Inc have traded over $14,451,171 worth of Sutro Biopharma Inc stock and bought 750,858 units worth $10,652,478 . The most active insiders traders include Corp /De/ Celgene, John Gordon Freund e Daniel Janney. On average, Sutro Biopharma Inc executives and independent directors trade stock every 19 days with the average trade being worth of $129,762. The most recent stock trade was executed by Jane Chung on 9 August 2024, trading 18,750 units of STRO stock currently worth $86,438.
at sutro biopharma we have pioneered a compelling and unique way of discovering, developing and manufacturing therapeutics. our focus is aimed primarily on next generation cancer therapeutics — antibody conjugates and bispecific antibodies. unconstrained by traditional methods of cell-based discovery, we can design and develop targeted medicines by innovating outside the constraints of the cell. our technology enables us to iteratively discover and test molecules in a rapid cycle of weeks rather than months, to rapidly identify the optimal molecule designed for safety and potency. our approach to discovery, without the cell, is also transcending the the limitations of biologics manufacturing. sutro has the world’s only cgmp cell-free manufacturing facility located in san carlos, california. this state-of- the-art facility confers an important competitive advantage as we head into human clinical trials in 2018. in addition to developing our own oncology pipeline, sutro biopharma is coll
Sutro Biopharma Inc executives and other stock owners filed with the SEC include: